Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrimycin for Severe COVID-19
NCT04672564Phase 3Terminated
- Sponsor
- Shenyang Tonglian Group
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Allosteric Modulators
- Countries
- 6
01
Overview
A Phase 3 trial of carrimycin in coronavirus disease 2019 (COVID-19), sponsored by Shenyang Tonglian Group. Started Mar 2021; status: terminated.
02
Drugs
carrimycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04672564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672564.